Low-dose cadmium activates the JNK signaling pathway in human renal podocytes

XIAOCUI CHEN¹, YINGHUA XU², ZUOWANG CHENG², HONG SU³, XIU LIU⁴, DONGMEI XU³, CAROLYN KAPRON⁵ and JU LIU¹

¹Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014; ²School of Graduate Studies, Taishan Medical College, Tai'an, Shandong 271000; ³Department of Nephrology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014; ⁴Department of Cardiography, Binzhou Medical University Affiliated Hospital, Binzhou, Shandong 256600, P.R. China; ⁵Department of Biology, Trent University, Peterborough, ON K9J 7B8, Canada

Received January 14, 2017; Accepted January 24, 2018

DOI: 10.3892/ijmm.2018.3445

Abstract. Cadmium (Cd) is an environmental toxin. Our previous study demonstrated that low-dose Cd damages the integrity of the glomerular filtration barrier (GFB); however, the underlying mechanisms are poorly understood. Podocytes are a major component of the GFB, which regulate the passage of proteins. The present study aimed to investigate the effects of low-dose Cd on human renal podocytes (HRPs). HRPs were treated with Cd and activation of the c-Jun N-terminal kinase (JNK) pathway was examined by western blot analysis. Proliferation, viability and apoptosis of HRPs were evaluated by MTT assay, trypan blue exclusion assay and flow cytometry, respectively. The properties of HRPs were validated by immunofluorescence staining and Phalloidin-labeling. The results indicated that 4 µM Cd may activate the JNK pathway, and increase the protein expression levels of c-Jun and c-Fos. However, proliferation, viability, apoptosis and alignment of the F-actin cytoskeleton in HRPs were not significantly affected by Cd treatment, with or without SP600125 pretreatment. In addition, the expression levels of CD2-associated protein and synaptopodin, which are differentiation markers of HRPs, remained unchanged following Cd treatment. These results indicated that low-dose Cd activates the JNK pathway but does not significantly affect HRP function.

Introduction

Cadmium (Cd) is an environmentally abundant toxic metal, which is considered a serious threat to human health (1). Cd has a long biological half-life, and exhibits organ accumulation. One of the primary target organs of Cd is the kidney (2). In addition to accumulation in proximal tubular cells, Cd exposure directly damages the glomerulus, thus resulting in proteinuria (3). However, little is currently known regarding the molecular mechanisms underlying its cytotoxic effects.

The glomerular filtration barrier (GFB) consists of fenestrated endothelial cells, the glomerular basement membrane and podocyte slit diaphragms (4). It achieves size selectivity of the glomerular filter, permitting filtration of water and small-sized solutes in the plasma (5). Surrounding the glomerular capillaries, podocytes are highly specialized epithelial cells that maintain the structural and functional integrity of the GFB. As interdigitating foot processes separated by a slit diaphragm, podocytes regulate the passage of proteins from the capillary lumen to Bowman's space (6). Podocyte dysfunction impairs size selectivity of the glomerular filter, thus leading to proteinuria, hypoalbuminuria and edema (5). In addition, podocyte phenotype is determined by the expression of CD2-associated protein (CD2AP) and synaptopodin (7). Podocyte dedifferentiation over the course of collapsing focal segmental glomerulosclerosis results in the loss of synaptopodin and cytoskeleton markers (8,9). Oxidized low-density lipoprotein stimulation re-organizes F-actin filaments and promotes podocyte migration in a focal adhesion kinase (FAK)-dependent manner (10).

Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine protein kinases, which regulate numerous biological cellular processes, including cell proliferation, apoptosis and F-actin cytoskeletal formation (11). The three major MAPK pathways in mammalian cells are extracellular signal-regulated kinases, c-Jun N-terminal kinase (JNK) and p38 MAPK (11). JNK, also termed stress-activated protein kinase (SAPK), is activated by stress signals, including heat shock, ultraviolet light, osmotic stress and metabolic toxins (12-14). Activated JNK translocates to the nucleus and activates c-Jun and c-Fos, thus resulting in the formation

The present study aimed to examine the effects of low-dose Cd (4 \( \mu \)M) on human renal podocytes (HRPs). The results indicated that Cd activates the JNK pathway, thus increasing c-Jun and c-Fos expression. However, Cd had no effect on proliferation, viability, apoptosis and alignment of the F-actin cytoskeleton of HRPs. In addition, treatment with SP600125, a JNK inhibitor, alongside Cd did not alter cell proliferation, viability, apoptosis and alignment of the F-actin cytoskeleton of HRPs compared with SP600125 treatment alone.

Material and methods

**Cell culture.** HRPs were originally provided by Dr MA Saleem (University of Bristol, Bristol, UK), and were cultured in RPMI-1640 medium (Corning, Inc., Corning, NY, USA) supplemented with 10% fetal bovine serum (Gibco™; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 \( \mu \)g/ml streptomycin. The cells were grown in a humidified atmosphere containing 5% CO\(_2\) at 37\(^\circ\)C. CdCl\(_2\) was purchased from Sigma-Aldrich; Merck KgaA (Darmstadt, Germany) and was dissolved in PBS, with a stock concentration of 1 mM. In the present study, 4 \( \mu \)M CdCl\(_2\) was considered low-dose treatment. SP600125 was purchased from Cell Signaling Technology, Inc. (Danver, MA, USA) and was dissolved in dimethyl sulfoxide. Cells were pretreated with 10 \( \mu \)M SP600125 for 1 h prior to treatment with Cd. Control cells were only treated with 10 \( \mu \)M SP600125 for 1 h. Experimental cells were pretreated with 10 \( \mu \)M SP600125 for 1 h, and then were treated with Cd for 1, 2, 6, 12 and 24 h. All treatments were at 37\(^\circ\)C.

**Western blotting.** Protein samples were extracted from HRPs using radioimmunoprecipitation assay buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 50 mM NaF, 1% NP-40, 0.1% deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM EDTA) supplemented with the protease inhibitors aprotonin (1 \( \mu \)g/ml), leupeptin (10 \( \mu \)g/ml) and phenylmethylsulfonyl fluoride (1 mM). Equal amounts of protein (40 \( \mu \)g; protein concentration was determined using BCA assay (Bio-Rad, Hercules, CA, USA)) were separated by 8% SDS-PAGE (Beyotime Institute of Biotechnology, Haimen, China) and were then transferred onto a polyvinylidene fluoride membrane. The membrane was blocked with 5% non-fat milk in Tris-buffered saline containing 1% Tween-20 (TBST; Cell Signaling Technology, Inc.) at room temperature for 2 h prior to incubation with primary antibodies overnight at 4\(^\circ\)C. After washing three times with TBST, the membrane was incubated with a peroxidase-conjugated secondary antibody at room temperature for 2 h. The primary antibodies used in the present study were as follows: Rabbit anti-SAPK/JNK (9258), rabbit anti-phosphorylated (p)-SAPK/JNK (4668), rabbit anti-c-Fos (2250), rabbit anti-c-Jun (9165) and rabbit anti-GAPDH (2118) (Cell Signaling Technology, Inc.). The secondary antibody used was goat anti-rabbit immunoglobulin G (7074; Cell Signaling Technology, Inc.). The immunoblots were developed using enhanced chemiluminescence reagents (EMD Millipore, Billerica, MA, USA), and relative blot intensities were semi-quantified using ImageJ software (version 1.4.3.67; National Institutes of Health, Bethesda, MA, USA).

**Cell proliferation and viability assay.** HRP proliferation was evaluated using the MTT assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) according to the manufacturer's protocol. Briefly, HRPs were plated at a density of 9x10\(^3\) cells/well in a 96-well plate and were cultured overnight. Subsequently, the cells were treated with Cd, SP600125 or a combination of Cd and SP600125 for 24 h, after which 10 \( \mu \)l MTT solution was added to each well and incubated for 4 h at 37\(^\circ\)C. The combination of SP600125 and Cd treatment was as follows: cells were pretreated with SP600125 for 1 h, and then co-treated with Cd and SP600125 for 24 h. The crystals were solubilized by the addition of 110 \( \mu \)l DMSO, and colorimetric intensity was analyzed using a 96-well plate reader (Molecular Devices, LLC, Sunnyvale, CA, USA) at a wavelength of 490 nm.

**HRP viability was assessed using a trypan blue exclusion assay.** Following treatment, HRPs were washed and incubated in 0.05% trypsin for 2 min at 37\(^\circ\)C. Subsequently, the cells were disaggregated into a single cell suspension and dilute 9:1 with 0.4% trypan blue (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China). The percentage of unstained cells was determined using an OLYMPUS CKX41 microscope (Olympus Corporation, Tokyo, Japan).

**Immunofluorescence.** HRPs were grown until confluent (80%) on fibronectin-coated glass chamber slides and were then treated with 4 \( \mu \)M Cd for 24 h. The medium was then aspirated, and monolayers were washed with PBS, fixed with 4% paraformaldehyde at room temperature for 20 min and washed three times with PBS for 15 min. Subsequently, the cells were permeabilized with 0.3% Triton X-100 for 10 min, washed three times with PBS for 15 min and incubated with a rabbit polyclonal antibody against CD2AP (1:50; #2135; Cell Signaling Technology, Inc.) or synaptotagmin (1:50; ab224491; Abcam, Cambridge, MA, USA) overnight at 4\(^\circ\)C. The cells were then incubated with an Alexa Fluor 546-labeled donkey anti rabbit secondary antibody (1:200; A10040; Thermo Fisher Scientific, Inc.) for 2.5 h at room temperature. Images of the slides were captured using an Olympus FXXS100 Imaging system (Olympus Corporation) with an excitation wavelength of 546 nm.

**Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) analysis.** Apoptosis of the HRPs was determined by Annexin V-FITC and PI staining using an assay kit (Neobioscience, Shenzhen, China) according to the manufacturer's protocol. Briefly, following treatment with Cd, SP600125 or a combination of Cd and SP600125 for 24 h, cells were trypsinized and resuspended into a single cell suspension. Subsequently, 1x10\(^3\) cells were stained with Annexin V-FITC (0.025%) for 3 min and PI (20 \( \mu \)g/ml) for 10 min at room temperature in the dark. Positive staining of the cells was detected using a FACS Aria II flow cytometer, and data were analyzed using the FACSDiva acquisition and analysis software (v6.1.3) (both from BD Biosciences, San Jose, CA, USA).

**Phalloidin-labeling.** HRPs were grown until confluent (80%) on fibronectin-coated glass chamber slides. Following exposure to 4 \( \mu \)M Cd, SP600125 or a combination of 4 \( \mu \)M Cd and
SP600125 for 24 h, the medium was aspirated and the monolayer was fixed for 5 min in 3.7% formaldehyde solution in PBS. The cells were then permeabilized with 0.3% Triton X‑100 in PBS, and stained with 5 µg / ml phalloidin‑tetramethylrhodamine B isothiocyanate (Sigma‑Aldrich; Merck KGaA) in PBS for 1 h at room temperature. DAPI staining was used to visualize the nuclei. Images were captured using a confocal microscope (LSM 880; Carl Zeiss AG, Oberkochen, Germany).

Statistical analyses. Data are presented as means ± SD. Statistical significance was assessed using one‑way analysis of variance followed by Tukey's post hoc test or Student's t‑test. Statistical analyses were performed using SPSS 17.0 statistical software package (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Low‑dose Cd activates the JNK pathway in HRPs. Cd activates JNK signaling and stimulates downstream effectors of JNK in HepG2 cells (17). In the present study, the effects of 4 µM Cd exposure on the JNK pathway in HRPs were determined by western blotting. The results indicated that the expression levels of p‑JNK were significantly increased following treatment of HRPs with 4 µM Cd for 6, 12 and 24 h. Conversely, the protein expression levels of total JNK and the internal control GAPDH remained unchanged (Fig. 1). In addition, the protein expression levels of c‑Jun and c‑Fos were significantly increased by Cd treatment (Fig. 2).

Low‑dose Cd exposure does not affect proliferation and the expression of cell type‑specific HRP markers. Cd inhibits the proliferation of numerous cell types (18,19). In the present study, the MTT assay was performed to examine the effects of Cd on HRP proliferation. The results indicated that 4 µM Cd did not significantly inhibit HRP proliferation after 24 h (Fig. 3A). The results of the trypan blue exclusion assay also demonstrated that HRP viability remained unchanged following Cd treatment (Fig. 3B). Specific markers of podocytes include CD2AP and synaptopodin (7). In response to extracellular stimuli, podocytes may undergo a phenotypic alteration, thus resulting in the loss of terminal differentiation markers (20,21). HRP characteristics were examined by immunofluorescence staining for CD2AP and synaptopodin. CD2AP and synaptopodin expression was unchanged in HRPs following 24 h exposure to 4 µM Cd (Fig. 3C). These results suggested that low‑dose Cd exposure may not alter the proliferation, viability and phenotype of HRPs.

Effects of low‑dose Cd combined with SP600125 on HRP proliferation and viability. SP600125 is a specific inhibitor of the JNK pathway (22). Co‑treatment with 10 µM SP600125 for 1 h inhibited Cd‑induced phosphorylation of JNK (Fig. 4A). Conversely, HRP proliferation and viability were similar in the group treated with a combination of SP600125 and Cd compared with in the group treated with SP600125 alone (Fig. 4B and C).

Effects of low‑dose Cd exposure on HRP apoptosis. The JNK pathway mediates apoptotic responses in numerous cell types (23). Following exposure to 4 µM Cd for 24 h, apoptosis of HRPs was examined by Annexin V‑FITC/PI double‑labeled flow cytometry. No significant alterations in the apoptotic rate were detected in Cd‑treated HRPs (Fig. 5). In addition, the apoptotic rate of HRPs treated with a combination of SP600125 and Cd was similar to that of HRPs treated with SP600125 alone. These results indicated that 4 µM Cd does not affect apoptosis of HRPs.

Effects of low‑dose Cd exposure on the F‑actin cytoskeleton of HRPs. Reorganization of the cytoskeleton is a hallmark
CHEN et al.: CADMIUM ACTIVATES THE JNK PATHWAY IN PODOCYTES

The present study examined the podocyte cytoskeleton by immunostaining the F-actin cytoskeleton-interacting molecule phalloidin. The results demonstrated that F-actin arrangement in podocytes treated with Cd was not disrupted compared with in the control group. Cd, cadmium; HRPs, human renal podocytes; n.s., not significant.

Figure 2. Cd increases the protein expression levels of c-Jun and c-Fos in HRPs. (A) Representative blots of c-Jun from HRPs treated with 4 µM Cd at various time-points. GAPDH was used as a loading control. (B) Densitometric analysis of c-Jun/GAPDH. n=3. *P<0.05. (C) Representative blots of c-Fos from HRPs treated with 4 µM Cd at various time-points. GAPDH was used as a loading control. (D) Densitometric analysis of c-Fos/GAPDH. n=3. **P<0.01 vs. the control group. Cd, cadmium; HRPs, human renal podocytes; n.s., not significant.

Figure 3. Effects of Cd on proliferation, viability and the expression of cell type-specific markers of HRPs. (A) MTT assay of HRPs treated with 4 µM Cd for 24 h. n=6. (B) Viability of HRPs following treatment with 4 µM Cd for 24 h. n=3. (C) Immunofluorescence staining of CD2AP and synaptopodin in HRPs treated with PBS (control) or 4 µM Cd for 24 h. Magnification, x200. Cd, cadmium; CD2AP, CD2-associated protein; HRPs, human renal podocytes; n.s. non-significant.

Figure 4. Effects of Cd in combination with SP600125 on HRP proliferation and viability. (A) Representative blots of p-JNK and total JNK from HRPs exposed to 4 µM Cd and pretreated with the JNK inhibitor SP600125. Cells treated with SP600125 alone were used as a control. (B) MTT assay of HRPs treated with 4 µM Cd for 24 h with or without SP600125 pretreatment. n=6. (C) Cell viability of HRPs treated with 4 µM Cd for 24 h with or without SP600125 pretreatment. n=3. Cd, cadmium; HRPs, human renal podocytes; JNK, c-Jun N-terminal kinase; n.s., not significant; p-JNK, phosphorylated-JNK.
sure to SP600125 and Cd, did not significantly alter F-actin arrangement in podocytes.

Discussion

Cd has been reported to induce toxicological effects in the human kidney (25). The present study aimed to explore the effects of low-dose Cd on HRPs, which are the major component of the GFB. The results demonstrated that treatment with 4 µM Cd increased phosphorylation of JNK, and the expression levels of c-Jun and c-Fos. However, Cd treatment did not affect the proliferation, viability, apoptosis and cytoskeleton of HRPs. In addition, inhibition of the JNK pathway did not significantly affect Cd-treated HRPs. These findings indicated that Cd activates the JNK pathway in podocytes but does not induce cytotoxic effects. Depending on the experimental settings, Cd may differentially affect specific cell types in the glomerulus (12,26). As previously reported, although the vascular system is the primary target of Cd toxicity, a low concentration of Cd does not affect the proliferation and apoptosis of human umbilical vein endothelial cells or human renal glomerular endothelial cells (HRGECs) (26-28). However, Cd may increase apoptosis of human renal mesangial cells (HRMCs) and decrease their proliferation (12). Podocytes are a terminally differentiated and highly specialized cell type in the glomerulus. Previous studies have suggested that podocyte proliferation may not be affected in response to injury (29,30). In addition, Cd affects cellular functions other than proliferation and apoptosis. A previous study demonstrated that low-dose Cd induces vascular hyperpermeability and disruption of endothelial barrier integrity via the Cd-induced membrane dissociation of vascular endothelial cadherin and β-catenin in HRGECs (26). Therefore, the effects of Cd on podocyte permeability require further investigation.

MAPKs are activated by numerous cellular stressors (11). Oxidative stress is one of the major mechanisms underlying Cd toxicity. The production of reactive oxygen species (ROS) induced by Cd causes severe toxic effects in numerous types of tissues and organs (31). JNK is one of the proteins activated in response to elevated ROS levels, which serves a critical role in the apoptotic process (32). At a concentration between 5 and 40 µM, Cd may induce apoptosis of BJAB cells by increasing DNA fragmentation and caspase-3 activity (33). In addition, at a concentration of 4 µM, Cd inhibits the proliferation of HRMCs via activation the JNK pathway (12). In the present study, treatment with 4 µM Cd increased phosphorylation of JNK, and c-Jun and c-Fos expression. However, activation of the JNK pathway did not induce apoptosis of HRPs. A previous study also indicated that Cd treatment increased p-JNK expression, but did not affect apoptosis of endothelial cells (26). Therefore, JNK-regulated cell functions may vary depending on cell type, stimulus, and the duration and strength
of kinase activities (31,34). In addition to MAPKs, the phosphatidylinositol 3-kinase/Akt pathway, hypoxia inducible factor-1α and nuclear factor-κB are involved in Cd-induced signal transduction (35-37). Activation of other signaling pathways may compensate the effects mediated by the JNK pathway.

An intact actin cytoskeleton is crucial for the maintenance of podocyte membrane tension, shape and glomerular function, and is associated with signaling events at the slit diaphragm (38). F-actin is one of the major components of the cytoskeleton (39). Synaptopodin is a proline-rich protein that is expressed in differentiated podocytes and orchestrates actin organization through its interaction with F-actin (40,41). JNK is associated with cytoskeletal integrity, and is involved in 4-hydroxy-2-nonenal-mediated actin remodeling in endothelial cells (42). In the present study, Cd activated the JNK pathway, and increased the expression levels of c-Jun and c-Fos, but had no significant effect on synaptopodin distribution. A previous study also reported that the F-actin cytoskeleton was unchanged in HRMCs by Cd treatment, despite activation of the JNK pathway (12). Numerous signaling cascades may be involved in reorganization of the actin cytoskeleton (43). For example, high glucose-induced F-actin rearrangement in mouse podocytes was mediated by activation of the Fyn/Rho-associated coiled-coil forming protein kinase signaling pathway (44). Furthermore, the FAK/p38 signaling pathway regulates cytoskeletal rearrangement in mouse podocytes (10). Therefore, activation of the JNK pathway may not be sufficient for rearrangement of the F-actin cytoskeleton in podocytes.

In conclusion, although low-dose Cd increased the phosphorylation of JNK, and the expression levels of c-Jun and c-Fos, it had no significant effect on proliferation, apoptosis and F-actin cytoskeletal rearrangement of HRP. Further studies are required to address the molecular mechanisms underlying Cd-induced loss of glomerular barrier integrity.

Acknowledgements

Not applicable.

Funding

The present study was supported by grants from the Science and Technology Development Plan of Shandong Province (grant no. 2013GSF11805), the National Natural Science Foundation of China (grant no. 81370269) and the Shandong Taishan Scholarship (JL).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

JL conceived and designed the experiments; XC, YX, ZC, HS, XL performed the experiments; JL, XC, DX and CMK analyzed the data; JL, XC and CMK wrote the paper.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


